T (vWF) is known to have a major role in platelet adhesion to the subendothelium and to be the carrier of factor VI11 (FVIII) in plasma.',' The term von Willebrand disease (vWD) now defines a heterogeneous bleeding disorder in which the underlying pathogenetic mechanism is related to quantitative and/or qualitative abnormalities of vWF. Both endothelial cells and megakaryocytes synthesize vWF, and recent classifications of vWD are based on quantitative, structural, or functional abnormalities of plasma or platelet vWF.'.' These abnormalities are sought by the following laboratory tests: (1) measurement of vWF antigen (vWF:Ag) and ristocetin cofactor activity (vWF:RCo) in plasma and platelet; (2) determination of the threshold ristocetin concentration inducing platelet aggregation (RIPA) of platelet-rich plasma (PRP); (3) analysis of the electrophoretic pattern of vWF, including the evaluation of the percentage of high molecular weight (HMW) multimers and the characterization of the different bands of each multimeric unit. As stated recently by Ruggeri3 when proposing a new classification of vWD patients, most patients, named type I vWD, with dominant genetic transmission have reduced amounts but no evident abnormality of plasma vWF. Some so-called severe type I or type I11 vWD patients have a dramatic quantitative abnormality of plasma vWF characterized by its recessive inheritance. The other patients, who are considered to have variant forms of vWD, have either low vWF:RCo level or enhanced response to ristocetin (RIPA increased); apart from the so-called subtype I New-Y~rk;~' their plasma vWF either has a reduced amount of H M W forms or none at all. When reinvestigating in depth a patient diagnosed with vWD 18 years ago, we identified a new variant of vWD with no vWF quantitative abnormality, normal RIPA, and all plasma and platelet vWF multimers. The evaluation of the response of this patient to therapeutic FVIII/vWF concentrate infusion and the study of the FVIII/vWF interaction provided evidence that the FVIII deficiency of this patient is related to the inability of her plasma vWF to bind FVIII.
PATIENT AND METHODS
A 50-year-old French woman originating from Normandy was referred to us in August 1988, before thyroidectomy. Her hemorrhagic history dated from childhood when she had life-threatening bleeding at age 10 after tonsillectomy. At this time she had been diagnosed as having "Rosenthal disease." The diagnosis of vWD was raised later, when at age 32 she had a severe postpartum hemorrhage. Her bleeding symptoms also included epistaxis, hematemesis, and melena. Investigations done in August 1988 showed a prolonged activated partial thromboplastin time (APTT), but normal prothrombin and thrombin times. Her bleeding time (BT) was borderline, and her platelet count and platelet aggregation induced by ADP and collagen were normal. Routine analysis showed no abnormality of vWF and normal or subnormal levels of factors IX, XI, and XII, but provided evidence for an FVIII deficiency.
Her two children, a son and a childless daughter, and her parents were said to have no history of bleeding. Her parents, who were orphans, learned they were third cousins.
When she was seen again in September 1988 for gastrointestinal bleeding and in February 1989 for thyroidectomy, her routine laboratory data were confirmed. With her informed consent, she underwent a therapeutic trial. After infusion of 500 mL of Plasmion (Roger Bellon, Neuilly-Paris, France), 400 mL of her plasma were collected by automatic plasmapheresis before infusion of a high purity (HP), solvent/detergent (S/D)-treated FVIII/vWF concentrate6 (CRTS, Lille, France) at a dose of 24 FVIII:C IU/kg body weight (b.w.). Blood samples were collected before and at Case report.
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different times after infusion. On the basis of FVI1I:C data, she was infused 3 days later with the same batch and the same dose of FVIII/vWF just before thyroidectomy. She did not have any bleeding problem either during surgery or during the 10 days postsurgery period that was covered with 2,260 total units of FVII1:C (12 IU/kg bw every 3 days).
Carrier-free Na'251 was from Amersham International, Amersham, UK, Iodo-gen and Iodo-beads were from Pierce Chemical Co, Rockford, IL. Bovine serum albumin (BSA), RIA grade, was from Sigma Chemical Co, St Louis, MO. Leupeptin, N-ethylmaleimide (NEM), epsilon amino-caproic acid (EACA), benzoquinone, Triton X-100, and urea were purchased from Serva, Heidelberg, FRG. Sodium dodecyl-sulfate was from Biorad, Richmond, CA. Isogel agarose EF was from LKB AB, Bromma, Sweden. Agarose IEF, Sephacryl S-1000, and Mono S were from Pharmacia Fine Chemicals AB, Uppsala, Sweden. Ristocetin was from Diagnostics Stago, Asni&res, France. Polystyrene tubes (50 x 6 mm) were purchased from Sterilin Limited, Hounslow, UK. Simplate bleeding time devices, General Diagnostics, were purchased from Organon Teknika, Turnhout, Belgium. Purified human fibrinogen Antibodies. The rabbit polyclonal antibodies to human vWF used in this study were prepared as already des~ribed.~ A monoclonal antibody (MoAb) (MoAb-239) to human vWF was prepared in collaboration with Immunotech, Marseilles, France. It recognizes all multimeric forms of plasma vWF and has the particular property of binding vWF under physiologic conditions and releasing it under slightly alkaline nondenaturating conditions.' MoAb-12G10 to FVIII was prepared in our institute as published by Croissant et aI9; it inhibits FVII1:C (-2,500 Bethesda U/mg MoAb) and was shown, by Western blotting, to be directed against the FVIII light chain." MoAb-12G10 was labeled with carrier-free NaIz5I according to the method of Fraker and Speck''; its specific radioactivity was 1 to 2.5 IrCi/pg.
Collection of blood and preparation of plasma samples. Venous blood was collected in 1:lO volume of 3.8% trisodium citrate. Platelet poor plasma (PPP) and PRP were prepared as described previously.I2 Routine coagulation tests were performed on fresh PPP or PRP. Remaining PPP samples were stored frozen at -25OC until further studied for vWF analysis in the 3 weeks after blood collection. A PPP sample was also prepared from a blood sample taken on sodium citrate with protease inhibitors: 5 mmol/L ethylene diamine tetra-acetic acid (EDTA), 6 mmol/L NEM, and 1 mmol/L leupeptin. For platelet vWF study, blood was collected on EDTA; platelets were prepared and washed during the 2 hours after blood collection and then lysed with Triton X-100 as previously described."
Tests for hemostasis were done by the methods in use at the coagulation laboratory of Amiens hospital, France. Most of them have been described e1~ewhere.l~ They included BT performed with the template modification of the Ivy techniqueN4 and RIPA performed in PRP using 1, 0.75, and 0.5 mg/mL ristocetin. FVII1:C was assayed by one-stage (FVIII:C-1)'5 and two-stage (FVIII:C-2)'6 methods using a pool of citrated plasmas calibrated against the First International Reference preparation of FVIII-related activities in plasma (80/511, NIBSC, London, UK) as standard. Anti-FVII1:C inhibitory activity was sought by the Bethesda method.I7 FVIII antigen assay was performed with a solid phase immunoradiometric technique using human antibodies.I8
Reagents.
Routine coagulation tests. vWF analysis. vWF analysis included the determination of vWF:Ag by an enzyme-linked immunoassay (ELISA) already described," and the determination of vWFRCO by aggregometry using 1 mg/mL ristocetin and fresh-washed platelets.20 The multimeric composition of plasma and platelet vWF was analyzed and quantified by electrophoresis and densitometric scanning as recently described.2' In brief, SDS-electrophoresis was performed using a mixture of 2 commercial agaroses (see Reagents) at 0.8% concentration for the stacking gel and 2.5% concentration for the running gel, as previously published.22 After electrophoresis, gels were fixed, washed, and overlaid with '2SI-labeled anti-vWF polyclonal antibodies. The intensity of the bands visualized by subsequent autoradiography was quantified by densitometry with a Helena P24 scanner. The HMW multimers of vWF were assumed to be the bands numbered 6 and above, and their percentage was deduced from computerized areas of scanning profiles. The binding of plasma vWF to normal platelets in the presence of ristocetin was evaluated as published23 by measuring residual vWFAg in the supernatants with our usual ELISA assay." The binding of plasma vWF to soluble type I and 111 human collagen, purified as already publishedz4 and immobilized on microplates, was studied as described by Brown and Bosak," but using our peroxydase-conjugated anti-vWF polyclonal antibodie~.'~ Plasma vWF was purified as previously mentioned26 using immunoaffinity on anti-vWF MoAb-239. Forty milliliters of individual citrated plasma was passed through separate columns containing 5 mL of Sephacryl S-1000 on which 4.3 mg of MoAb-239 had been coupled, according to the method of Brandt et al. 27 After washing with 0.25 mol/L NaCl and eluting FVIII with 0.35 mol/L calcium vWF was eluted with 0.25 mol/L NaCl solution extemporaneously adjusted to pH 11 with ammonia solution. The eluted fractions were immediately neutralized and concentrated by dialysis against 1.6 mol/L ammonium sulfate pH 7.0 for 2 days at 4OC. The day before being used in the test for FVIII/vWF interaction, vWF was harvested by centrifugation and dialyzed overnight against 50 mmol/L phosphate buffer, pH 7.5.
Purified vWF with a specific activity (SA) of 120 vWFAg IU/mg was prepared from cryoprecipitate (CRTS) as described previously? It was labeled with carrier-free NaIZSI and Iodo-bead according to the procedure described by the manufacturer to obtain a specific radioactivity -0.5 rCi/pg.
Human FVIII was isolated from FVIII/ vWF concentrates (CRTS) by immunoaffinity on anti-FVIII MoAb-12G10 and subsequent purification by ion exchange on a Mono S column as described previou~ly.~~ The final preparation (SA > 2,000 FVII1:Ag IU/mg) contained 10 to 80 IU/mL FVIII:C, 70 to 450 IU/mL of FVIII:Ag, and no detectable vWF (~0 . 0 1 vWF:Ag IU/mL).
An immunoradiometric test was performed according to the method described previouslyz9 with purified plasma vWF and FVIII obtained as described above. Some modifications were made to quantify immobilized vWF. Two series, A and B, of polystyrene tubes were coated overnight with 200 pL of purified vWF obtained from the normal and patient's plasma, and diluted (3 x lO-'to 1 vWF:Ag IU/mL) in 50 mmol/L phosphate buffer, pH 7.5. In control experiments, purified vWF (SA = 120 vWF:AgIU/mg) obtained from therapeutic cryoprecipitate or other purified plasma proteins (immunoglobulins, fibrinogen, and fibronectin) diluted from 32 to 0.5 pg/mL were coated under the same conditions. In the tubes of series A, purified (SA = 120 vWFAgIU/mg) labeled vWF (-6,000 cpm) used as tracer was mixed with all the dilutions. All the tubes were then incubated for 2 hours at room temperature with 6% BSA in vWF purification.
FVIII purijcation.
Binding of puriJied FVIII to vWF-coated tubes. 
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RESULTS
Routine laboratory evaluation.
The coagulation tests performed on three occasions are summarized in Table 1 and in the Case Report. It is noteworthy that APTT values were prolonged as a function of FVII1:C decrease. FVI1I:C-I, FVll I:C-2, and FVII1:Ag levels were similar. Bleeding time was slightly prolonged on one occasion, but strictly normal a t two other times. No anti-FVII1:C inhibitory activity was detected in PPP heated for 30 minutes at 56OC. Furthermore, vWF:Ag and vWF:RCo levels and RIPA were always normal.
The availability of a small amount of PPP from the patient's son allowed us to measure some of his FVIII/vWF-
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--- The patterns of vWF obtained after SDS-agarose electrophoresis of the patient's PPP were also normal (Fig I) . The percentages of HMW multimers (numbered 6 and above) of vWF in two different samples of the patient's PPP were 56.6% and 53.8%, respectively, as compared with 56.8% and 52.8% for a pool of normal citrated plasmas analyzed in the same electrophoretic runs. The multimeric unit of plasma vWF, displaying the characteristic "quintuplet" pattern composed of two subbands flanking each side of the major bands,22 appeared normal in both patients' PPP samples ( Fig  I) . The multimeric pattern of the plasma vWF from the blood sample taken in the presence of protease inhibitors was similar (Fig 1 A) .
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In addition, the binding of the patients' plasma vWF to normal platelets in the presence of ristocetin and to collagen were also strictly normal (data not shown).
Further analysis of vWF. IU vWF:Ag of immobilized patients' vWF was necessary to obtain a similar FVIII binding. Furthermore, the FVIII binding to vWF prepared from normal plasma was dependent on the amount of vWF immobilized, and a similar 
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dose-dependent curve was obtained when vWF (SA = 120 vWF:AgIU/mg) purified from therapeutic cryoprecipitate was tested (data not shown).
The abnormality of FVIII binding to patients' vWF was confirmed using four purified vWF samples obtained from patient's PPP collected in September 1988 and February 1989, and four purified vWF samples prepared from four different normal individual plasmas.
To see if the dramatic decrease in binding of the vWF prepared from patients' plasma could be due to the presence of an inhibitor, coated normal vWF was incubated for 1 hour a t 37OC with either unheated or heated patients' PPP before addition of FVIII. No significant change in FVIII binding to normal vWF was noticed in either case (data not shown).
DISCUSSION
In light of the biologic results, the hemorrhagic syndrome of the patient described here appears to be essentially related to a decreased level of FVII1:C. The bleeding time is normal or borderline, which is in accord with the fact that no quantitative or qualitative plasma or platelet vWF defect could be demonstrated by the conventional tests. Such results, together with the fact that FVII1:Ag and FVII1:C levels are identical, are usually found in hemophilia A carriers in whom "Lyonization" accentuates the FVIII deficiency and is responsible for an FV1II:vWF ratio of less than 0.75.31 They could also be compatible with the presence of anti-FVII1:C antibodies. Nevertheless, these diagnoses could be discarded given the impossibility of demonstrating anti-FVII1:C activity in the patients' PPP and the patient's response to the infusion of FVIII concentrates. In fact, the persistence of a high FVII1:C level 24 and even 48 hours after infusion proves that the biologic abnormalities are due not to a defect in the synthesis of functional FVIII (as in hemophiliacs or hemophilia carriers in whom the exogenous FVIII has a half-life of around 8 to 12 hrs3*) nor to the presence of an inhibitor causing low FVIII recovery and half-life. On the contrary, this response, which also shows very high FVII1:C recovery levels with a peak only two hours after infusion, is an example of the sustained paradoxal rise in FVIII usually experienced with vWD patients. It is generally interpreted as being due to an effect of the exogenous vWF on the protection or the synthesis of the patient's FVIII.'332 Therefore, these results led us to hypothesize that an abnormality of the patient's vWF, and not of the FVIII itself, was the explanation for the FVIII deficiency. Using plasma vWF purified approximately 1,300 times by immunoaffinity, we were able to show that the patient's vWF was unable to bind FVIII normally. In contrast, vWF purified from normal plasma bound FVIII and this binding was demonstrated to be dependent on vWF: it did not occur on other purified plasma proteins and was reversible under the conditions known to dissociate FVIII/vWF complex. 33 Furthermore, no inhibitor of FVIII/vWF association was evidenced in either unheated or heated patient's plasma. This led us to conclude that patient's vWF failed to bind normal FVIII. To our knowledge, such a vWF defect has not yet been demonstrated in this way. Moreover, the patient's vWF binds normally to platelets and collagen, and the patient shows no signs of a primary hemostasis disorder: normal BT and no excessive bruising, gingival bleeding or menorrhagia, which are the most common symptoms, together with epistaxis in vWD women."* Therefore this patient has an abnormality of her plasma vWF leading to a hemorrhagic syndrome comparable with that of patients with an isolated FVIII deficiency (mild hemophilia A, hemophilia A carriers, acquired FVIII inhibitors). Nevertheless, considering the fact that her hemorrhagic diathesis results from a qualitative abnormality of her plasma vWF, this patient should be classified under type I1 vWD if the vWF qualitative defect is no longer restricted to a lack of H M W m~l t i m e r s .~ Furthermore, as this variant illustrates a new physiopathologic mechanism of FVIII deficiency (ie, qualitative, without quantitative abnormality of vWF limited to its ability to bind FVIII), we tentatively suggest it be named not simply by a new letter but by the term "Normandy" after the patient's birth province.
Because no complete family study could be done before now, we have no precise information on the transmission of this abnormality. Since none of the parents or the two children had hemorrhagic problems, if the abnormality is due to a defect of the vWF gene and not to a posttranscriptional abnormal event, the following hypotheses can be presented: (1) mutation occurred of a dominant character of the vWF gene of one of the two chromosomes 1234 of the patient, and none of the children received this chromosome from their mother; (2) there is, as is presumed in type IIC vWD patient^,'**^^^'^ a double heterozygosity for two mutant alleles inherited in an recessive manner: one could be a "null" vWF gene and the other a gene inducing the synthesis of abnormal vWF; (3) there is homozygosity of a recessive abnormality of the vWF gene. The last two hypotheses fit in with the patient's son's preliminary data (normal level of vWF but decreased level of FVIII), given that he could be heterozygous for the vWF gene abnormality explaining the defect of the FVIII/vWF interaction. However, the homozygosity of our patient seems to be the most likely hypothesis because her parents were probably blood-related.
The study of this patient's DNA with specific probes of the vWF gene will soon be undertaken to search for a possible mutation or deletion of the nucleotide sequence. The characterization of such a defect could enable a possible abnormality to be inferred at the level of the vWF molecule itself. Another more direct approach involves locating the vWF structural abnormality of this patient. The vWF domain binding to FVIII was located on the N-terminal part of the plasma vWF and persists in the tryptic or plasmic 34-Kd fragment made up of 272 AA containing several intrachain disulfide bonds and one N-glycanic hai in.^'.^' Our research, currently in progress, is therefore directed toward a comparison of the tryptic fragments obtained from normal and patients' vWF.
Although the molecular abnormality of vWF, and possibly of its gene, still have to be defined, we can assume that we demonstrated a new autosomal defect explaining FVIII deficiency. Therefore, we believe that certain patients diag-nosed as mild hemophilia A, for whom there is no data clearly indicating an FVIII half-life of around 10 hours after transfusion Or a family history Of obvious sex-linked recessive transmission, may in fact have the Same VWF abnormality as the patient described here. A current study is being done to reinvestigate such patients to determine whether their plasma vWF is able to bind FVIII.
